Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adriforant - Novartis

Next Previous
Drug Profile

Adriforant - Novartis

Alternative Names: NVP-ZPL389-NX; PF-03893787; PF-3893787; ZPL-389; ZPL-3893787; ZPL-3893797; ZPL389-NX

Latest Information Update: 10 Nov 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Novartis; Pfizer
  • Class Amines; Anti-inflammatories; Antiasthmatics; Antipsoriatics; Cyclopropanes; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 29 Oct 2020 Novartis terminates the phase II ZESTExt trial in Atopic dermatitis (Treatment-experienced) in Belgium, Czech Republic, Estonia, France, Germany, Iceland, Finland, Canada, Japan, Netherlands, Poland, Russia, Slovakia, Taiwan, United Kingdom and USA due to lack of efficacy (PO) (NCT03948334) (EudraCT2018-000595-15)
  • 21 Jul 2020 Novartis discontinues phase IIb ZEST trial in Atopic dermatitis (Treatment-experienced) in in Austria, Argentina, Belgium, Czech Republic, Estonia, France, Hungary, Russia, Taiwan, Slovakia, Poland, Germany, Japan, Canada, United Kingdom, Iceland, Finland, Netherlands, USA (PO) due to efficacy concern before July 2020
  • 04 Apr 2019 Novartis initiates a phase II extension trial in Atopic dermatitis (Treatment-experienced) in Finland, Germany, United Kingdom, USA, Iceland, Slovakia, Russia, Netherlands, Poland, Japan, Canada (PO) (NCT03948334) (EudraCT2018-000595-15) after April 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top